

AWARD NUMBER: W81XWH-16-1-0726

TITLE: A Randomized Controlled Trial of the Group-Based Modified Story Memory
Technique in TBI

PRINCIPAL INVESTIGATOR: Nancy D. Chiaravalloti, PhD

CONTRACTING ORGANIZATION: Kessler Foundation, East Hanover, NJ

REPORT DATE: October 2020

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2020		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2019-29Sep2020	
4. TITLE AND SUBTITLE A Randomized Controlled Trial of the Group-Based Modified Story Memory Technique in TBI				5a. CONTRACT NUMBER W81XWH-16-1-0726	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Nancy D. Chiaravalloti, PhD E-Mail:				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) KESSLER FOUNDATION, INC. 120 EAGLE ROCK AVE STE 100 EAST HANOVER NJ 07936-3147				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT <p>Impairments in new learning and memory are among the most common deficits in individuals with Traumatic Brain Injury (TBI) and have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. There is thus a tremendous need for the development of effective interventions for learning and memory dysfunction in TBI. This need has been recognized, as evident by a recent rise in studies examining the efficacy of memory retraining in persons with TBI. However, research to date has been limited to studies examining one-on-one intervention protocols. While the documentation of the efficacy of such treatment protocols represents a substantial contribution to the clinical care of persons with TBI, it has become evident that the clinical application of individual therapy for memory deficits in persons with TBI is limited by the availability of insurance payment for such services. That is, insurance companies are not willing to reimburse for individual cognitive rehabilitation sessions, but they do reimburse for group cognitive rehabilitation. There thus exists a critical need to document the efficacy of groupbased interventions for memory deficits in persons with TBI,</p>					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1
4. Impact.....	5
5.Changes/Problems.....	5
6. Products.....	6
7.Participants & Other Collaborating Organizations.....	6
8.Special Reporting Requirements.....	8
9. Appendices.....	8

1. **INTRODUCTION:**

Impairments in new learning and memory are among the most common deficits in individuals with Traumatic Brain Injury (TBI) and have been shown to exert significant negative impact on everyday life. There is thus a tremendous need for the development of effective interventions for learning and memory dysfunction in TBI, particularly group-based interventions for which 3rd party payment may be more forthcoming. The current study addresses this critical need through the conduct of a double blind, placebo-controlled, randomized clinical trial (RCT) of a group administration of the modified Story Memory Technique (mSMT). Over a decade of research and development conducted at our center has demonstrated the mSMT to be effective for improving new learning and memory in individuals with Multiple Sclerosis (MS) and TBI across three realms of functioning, objective behavior, brain functioning and everyday life. This convincing data provides Class I evidence supporting the efficacy of the mSMT for improving new learning and memory in these populations. Given the strong efficacy data on the mSMT, coupled with the current trends in insurance reimbursement, clinicians worldwide have highlighted the need to provide the mSMT via an effective group format. We have thus modified the treatment protocol for group administration. This pilot RCT tests the efficacy of a group administration of the mSMT for persons with moderate to severe TBI.

2. **KEYWORDS:**

Memory, TBI, cognition, cognitive rehabilitation, cognitive retraining, new learning, treatment

3. **ACCOMPLISHMENTS:**

What were the major goals of the project?

The current study addresses the following specific aims.

Aim 1. Objectively evaluate the efficacy of the group mSMT to improve new learning/memory in individuals with TBI with documented deficits in this area.

Aim 2. Increase the generalizability and real life application of the group mSMT by assessing outcome following group mSMT with global measures of everyday life, including one objective measure and multiple subjective measures.

Aim 3. Examine the neurofunctional changes resulting from the group-based mSMT in TBI subjects with impairments in new learning and memory. We will examine if neurofunctional changes in the brain are associated with behavioral improvements following the mSMT and if these changes are maintained over time.

Aim 4. Evaluate the long-term efficacy of the group mSMT through a 3-month follow-up.

To accomplish these aims, the following major tasks were identified:

- *Major Task 1:* Administratively Prepare for Clinical Trial
 - *Target completion date:* 1/1/17
 - *Actual completion date:* 1/1/17
 - *Percent of completion:* 100%

- Major Task 2: Coordinate Study Staff for Clinical Trial
 - Target completion date: 4/1/17
 - Actual completion date: 4/1/17
 - Percent of completion: 100%
- Major Task 3: Prepare Research Protocol
 - Target completion date: 2/1/17
 - Actual completion date: 2/1/17
 - Percent of completion: 100%
- Major Task 4: Participant Recruitment, Treatment, Participant Evaluation
 - Target completion date: 9/30/21
 - Actual completion date: n/a
 - Percent of completion: 37% (22 participants of 60 targeted)
- Major Task 5: Data Analysis
 - Target completion date: 9/30/21
 - Actual completion date: n/a
 - Percent of completion: n/a

What was accomplished under these goals?

1) Major Activities:

	Deadline	Status
Major Task 1: Administratively Prepare for Clinical Trial	1/1/17	complete
Major Task 2: Coordinate Study Staff for Clinical Trials	4/1/17	complete
Major Task 3: Prepare Research Protocol	2/1/17	complete
Major Task 4: Participant Recruitment, Treatment, Participant Assessment	9/30/21	ongoing

2) Specific Objectives:

	Deadline	Status
Major Task 1: Administratively Prepare for Clinical Trial		
Subtask 1: Prepare Regulatory Documents and Research Protocol		
Finalize consent form & human subjects protocol	1/1/17	complete
Submit protocol to IRB	1/1/17	complete
Submit protocol for Military IRB Review (ORP/HRPO)	4/1/17	complete
Submit amendments, adverse events and protocol deviations as needed	As needed	
Coordinate with Sites for annual IRB report for continuing review	Annually	

<i>Milestone Achieved: Local IRB approval at KF</i>	1/1/17	complete
<i>Milestone Achieved: HRPO</i>		
Major Task 2: Coordinate Study Staff for Clinical Trials		
Subtask1: Hiring and Training of Study Staff		
Prepare job description design	11/1/16	complete
Advertise and interview for project related staff	1/1/17	complete
Coordinate for space allocation for new staff	1/1/17	complete
<i>Train staff for treatment and assessment activities</i>	3/1/17	complete
<i>Milestone Achieved: Research staff trained</i>	4/1/17	complete
Subtask 2: Facilitate hiring, training, supervision and fidelity checks as needed for attrition and treatment fidelity	ongoing	
<i>Milestone Achieved: Maintained trained and available staff throughout duration of clinical trial</i>	ongoing	
Major Task 3: Prepare Research Protocol		
Finalize administration procedures for group mSMT	2/1/17	complete
Finalize assessment procedures; assemble testing binders and testing files for NPE and AGF	2/1/17	complete
Ensure appropriate programming of ePrime stimulus delivery of neuroimaging stimuli	2/1/17	complete
Finalize timing and parameters for the collection of optimal imaging data	2/1/17	complete
Milestone Achieved: both outcome assessments and treatment protocol finalized and running smoothly	ongoing	
Major Task 4: Participant Recruitment, Treatment, Participant Evaluation		
Subtask 1: Participant recruitment & enrollment		
Begin recruitment and screening of appropriate potential participants for study participation	4/1/17	complete
<i>Milestone Achieved: 1st 3-5 participants consented, screened and enrolled</i>	5/1/17	complete
<i>Milestone Achieved: First group treatment period completed successfully</i>	7/1/17	complete
Recruitment and screening continues	ongoing	ongoing
Participants complete assigned condition group treatment to reach target n of 60	ongoing	ongoing
Complete follow-up assessments 3 months after completion of treatment	ongoing	ongoing
<i>Milestone Achieved: Data collection complete; data analysis begins</i>	9/30/20	ongoing

3) Significant results or key outcomes:

Data collection is ongoing and has been progressing well. We have encountered slowed enrollment and we have tried several means of addressing this. This is a very difficult study to recruit for because individuals have to come to Kessler for treatment and because it is a group treatment, their schedules need to coincide. We have begun to recruit off-site at day treatment programs (clubhouse). This has increased enrollment somewhat and we will thus continue. The COVID-19 pandemic resulted in research stopping completely for several months. Once we re-initiated our study, patients were very hesitancy to physically come to Kessler to

participate. We therefore requested permission to administer the treatment and assessments virtually, which was approved. We will be beginning virtual groups in the coming months.

4) other achievements.

As summarized above, given that this is a randomized clinical trial (RCT), there are several aspects to the protocol that required attention. The initial grant year tackled these tasks, including preparing regulatory documents and the research protocol, coordinating the study staff for the clinical trial (hiring, training, advertising for the study, compiling all assessment and training protocols, coordinating space allocation, and identifying technological needs and capabilities), and preparation of the research protocol. Finally, participant recruitment, testing and enrollment could be initiated. The 2nd year of the grant focused on participant recruitment, screening and enrollment. Recruitment has been increasingly difficult, detailed below. We thus added a 2nd performance site, a clubhouse in Milburn, NJ, which helped recruitment. At this point, we have moved the study to an online format, which has helped recruitment in the current COVID-19 environment.

Recruitment details:

- 415 people with moderate to severe TBI were contacted for potential participation in the study.
 - 69 were background screened
 - Thirty-three (33) didn't qualify based on background screen.
 - Forty (40) qualified based on the background screen
 - Twenty-nine (29) were willing to complete the in-person screen
 - Three (3) failed in-person screen
 - Two (2) chose not to participate after passing the in-person screen
 - Twenty-five (25) people passed the screenings and were enrolled
 - Seventeen (17) participants completed the study
 - Three of the 17 also completed the imaging assessments at baseline and one of the two also complete the follow-up scans.
 - Seven (7) additional participants dropped out after completing the baseline assessment
 - 78 were not interested due to time commitment or couldn't travel to us
 - 196 could not be reached after multiple attempts and did not return our calls
 - 22 moved out of state or could not travel to appointments
 - 5 asked to be called back in a few weeks or months
 - 40 did not qualify based on information garnered during a casual conversation (e.g. had a stroke rather than TBI)

What opportunities for training and professional development has the project provided?

This project was not intended to provide training and professional development. However, staff recruited for the study include bachelor's level research assistants that received substantial on-the-job training in neuropsychological assessment, working with persons with TBI and the cognitive rehabilitation protocol being studied. This is done through one-on-one work with a mentor and results in increased knowledge or skill in neuropsychological assessment and functioning. All study staff additionally participate in the semi-annual TBI Consumer Conference held and have many opportunities to attend lectures and workshops at Kessler or Rutgers University.

How were the results disseminated to communities of interest?

Nothing to Report. Data collection is ongoing.

What do you plan to do during the next reporting period to accomplish the goals?

Goals for the next reporting period continue to focus on participant recruitment, enrollment and treatment. We have moved the study to a virtual format and will continue to run groups via Zoom for Healthcare. We also continue to work with our patient recruitment specialist to increase awareness of the study in the TBI Community and hopefully referrals for participation.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Nothing to Report. Data collection is ongoing.

What was the impact on other disciplines?

Nothing to Report. Data collection is ongoing.

What was the impact on technology transfer?

Nothing to Report. Data collection is ongoing.

What was the impact on society beyond science and technology?

Nothing to Report. Data collection is ongoing.

5. CHANGES/PROBLEMS:

While we are exploring different options for recruiting participants, this will not involve any changes to the study protocol. All methodology will remain as proposed.

Changes in approach and reasons for change

none

Actual or anticipated problems or delays and actions or plans to resolve them

An anticipated delay was the delay in recruitment that we have already encountered and is being addressed. The COVID-19 pandemic was an unanticipated problem causing a substantial delay. However, the transition of the study to an online format has aided in addressing that challenge.

Changes that had a significant impact on expenditures

none

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

none

Significant changes in use or care of human subjects

none

Significant changes in use or care of vertebrate animals.

none

Significant changes in use of biohazards and/or select agents

none

6. PRODUCTS:

Nothing to Report. Data collection is ongoing.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Nancy Chiaravalloti, PhD; PI; no change

Glenn Wylie, D.Phil.; co-I; no change

John DeLuca, PhD; co-I; no change

Ekaterina Dobryakova, PhD; co-I; no change

Nancy Moore, MA; Research Manager; no change

Name:	<i>Alec DeGraaf</i>
Project Role:	<i>Research Assistant</i>
Nearest person month worked:	<i>4</i>
Contribution to Project:	<i>Mr. DeGraaf has been involved with participant recruitment and conducting the treatment sessions</i>
Funding Support:	<i>NIDILRR Field Initiated grant</i>
Name:	<i>Suzanne Zuckerman</i>

Project Role:	<i>Research Assistant</i>
Nearest person month worked:	5
Contribution to Project:	<i>Ms. Zuckerman has been involved with participant recruitment and conducting the Assessment sessions.</i>
Funding Support:	<i>NIDILIRR Field Initiated grant</i>
Name:	<i>Eric Stone</i>
Project Role:	<i>Research Assistant</i>
Nearest person month worked:	1
Contribution to Project:	<i>Mr. Stone has been involved with participant recruitment.</i>
Funding Support:	National MS Society and NJ Commission on TBI Research
Name:	<i>Tiffany Chang</i>
Project Role:	<i>Research Assistant</i>
Nearest person month worked:	2
Contribution to Project:	<i>Ms. Chang had been involved with participant recruitment and conducting the Assessment sessions. She has now left the organization.</i>
Funding Support:	<i>NIDILIRR Field Initiated grant</i>
Name:	<i>Michael Pellicane</i>
Project Role:	<i>Research Assistant</i>
Nearest person month worked:	2
Contribution to Project:	<i>Mr. Pellicane had been involved with participant recruitment and conducting the treatment sessions. He has now left the organization.</i>
Funding Support:	<i>NIDILIRR Field Initiated grant</i>

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to Report.

What other organizations were involved as partners?

None. Nothing to Report.

8. **SPECIAL REPORTING REQUIREMENTS**

none

9. **APPENDICES:**

none